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Abstract
Antidepressants demonstrate modest response rates in the treatment of major depressive disorder (MDD). Despite
previous genome-wide association studies (GWAS) of antidepressant treatment response, the underlying genetic factors
are unknown. Using prescription data in a population and family-based cohort (Generation Scotland: Scottish Family
Health Study; GS:SFHS), we sought to deﬁne a measure of (a) antidepressant treatment resistance and (b) stages of
antidepressant resistance by inferring antidepressant switching as non-response to treatment. GWAS were conducted
separately for antidepressant treatment resistance in GS:SFHS and the Genome-based Therapeutic Drugs for Depression
(GENDEP) study and then meta-analysed (meta-analysis n= 4213, cases= 358). For stages of antidepressant resistance,
a GWAS on GS:SFHS only was performed (n= 3452). Additionally, we conducted gene-set enrichment, polygenic risk
scoring (PRS) and genetic correlation analysis. We did not identify any signiﬁcant loci, genes or gene sets associated
with antidepressant treatment resistance or stages of resistance. Signiﬁcant positive genetic correlations of antidepressant
treatment resistance and stages of resistance with neuroticism, psychological distress, schizotypy and mood disorder
traits were identiﬁed. These ﬁndings suggest that larger sample sizes are needed to identify the genetic architecture of
antidepressant treatment response, and that population-based observational studies may provide a tractable approach to
achieving the necessary statistical power.
Introduction
Major depressive disorder (MDD) is a disabling condition
with a high global impact [1, 2]. Antidepressants are the
ﬁrst-line treatment for MDD patients but response is modest
with only approximately 50% achieving remission after
completing two treatments [3]. The mechanisms underlying
antidepressant resistance remain elusive but are of key value
if more effective therapies are to be identiﬁed and
developed.
Genome-wide association studies (GWAS) of anti-
depressant treatment response have yet to establish
any replicated genetic variants [4–10]. Two large meta-
analyses similarly reported no genome-wide signiﬁcant
associated variants. The ﬁrst, a meta-analysis of the
GENDEP (Genome-based Therapeutic Drugs for
Depression), MARS (Munich Antidepressant Response
Study) and the STAR*D (Sequenced Treatment Alter-
natives to Relieve Depression) [11] studies comprised of
2256 MDD cases, and the second, between the NEW-
MEDS (Novel Methods Leading to New Medications
in Depression and Schizophrenia) and STAR*D [7] pro-
jects comprised of 2897 MDD cases. An additional
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analysis in the ﬁrst meta-analysis restricted to
citalopram or escitalopram did, however, identify an
intergenic variant (5q.15.1) [11]. The largest GWAS to
date examining treatment resistance (n= 1311) versus
responders (n= 7795) was conducted by Li et al.
utilising self-report information from 23andMe and found
no signiﬁcantly associated genetic variants, although
found one variant (4.q22.1) associated with bupropion
response [12]. Numerous candidate genes have
also been investigated but the results are inconsistent [13].
Furthermore, the largest polygenic risk score (PRS)
analysis in antidepressant response to date, (which
utilised GENDEP/STAR*D data) yielded no
signiﬁcant associations for response itself, MDD or
schizophrenia [14].
Discovering genomic variants associated with resis-
tance to antidepressants could advance personal treatment,
help identify resistant individuals earlier and inform our
understanding of MDD. A recent systematic review
reported non-response was associated with illness severity
including higher suicide risk, number of hospitalisations
and antidepressant dosage, but not cognitive ability [15].
In fact, several phenotypic associations have been found
in treatment resistant individuals; more comorbidities and
suicide attempts [16], increased neuroticism and
decreased extraversion, openness and conscientiousness
[17, 18]. Identifying genetic loci may therefore help to
identify resistant individuals earlier and enable timelier
intervention.
Currently pharmocogenetic studies are limited by small
sample sizes [19] and low statistical power. Numerous
studies have indicated the need for large sample sizes in
genetic studies [20, 21]. The recent Li et al study max-
imised sample size by utilising self-report questionnaires
[12], whilst other groups have examined treatment resis-
tance in both MDD or schizophrenia by using prescription
data [22–24].
In the present study, we employed a complementary
approach utilising prescription data in a population and
family-based cohort (Generation Scotland: Scottish
Family Health Study; GS:SFHS) to deﬁne a dichotomous
and a semi-quantitative measure of antidepressant resis-
tance; treatment resistance and stages of resistance,
respectively. We conducted a GWAS of antidepressant
treatment resistance with meta-analysis with the GENDEP
cohort and stages of antidepressant resistance in GS:SFHS
only and calculated narrow-sense heritability estimates.
Gene and gene-set enrichment analysis on both traits were
also conducted and we further examined genetic correla-
tions. We also utilised PRS techniques to examine
pleiotropy between the genetic liability of MDD, schizo-
phrenia and bipolar disorder in antidepressant treatment
resistance and stages of resistance.
Methods
Cohort description
Generation Scotland: Scottish Family Health Study
GS:SFHS is a family and population-based cohort of 23,960
individuals (mean age= 47.6, s.d.= 15.4) within Scotland.
Participants were eligible if they were aged above 18 years
and had a ﬁrst-degree relative also willing to participate in
the study. Recruitment has been described in detail else-
where [25, 26]. Genotype data were available for 20,032
participants and data on mood, cognitive function and
personality traits were obtained through interview (see
Supplementary Materials). Brieﬂy, four cognitive tests
(digit symbol coding, vocabulary, verbal ﬂuency and logical
memory), neuroticism and extraversion (measured by the
Eysenck Personality Questionnaire), schizotypal personality
questionnaire (SPQ), mood disorder questionnaire (MDQ),
Scottish Index of Multiple Deprivation (SIMD) and number
of years in education were all assessed. MDD was measured
by structured clinical interview for DSM-IV (SCID) given a
positive screening during the original interview (further
details in Supplementary Materials).
Prescription data were available through data linkage to
the Prescribing Information System administered by
National Health Service (NHS) Scotland Information Ser-
vices Division. Written informed consent for linkage was
obtained for 98% of GS:SFHS and only those individuals
that provided informed consent were analysed. Further
information regarding the prescription records are found in
the Supplementary Materials (see Supplemental Table S1
and S2). To deﬁne all MDD antidepressant users, records
were excluded if the daily dose was below the minimum
recommendations given by the British National Formulary
(BNF) for MDD [27] and the duration was below 6 weeks
of continuous treatment (as this is considered adequate
duration [28, 29]). Following this pruning, we totalled the
number of different antidepressants prescribed to each
individual. This was then used as a measure of non-
response, assuming that switching to a different anti-
depressant reﬂected failure or lack of clinical response.
Drug switching due to side effects is expected to take place
before the 6th week of treatment. Individuals with schizo-
phrenia, schizoaffective disorder and bipolar disorder were
excluded (n= 164). Additionally, antidepressants per indi-
vidual were each deﬁned as a “prescription episode”
whereby uninterrupted prescriptions for the same anti-
depressant are considered one prescription episode. This
was done in order to differentiate a repeat prescription for
one episode from multiple depression episodes where the
same antidepressant was given on more than one occasion
(more information in the Supplementary Materials).
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Deﬁning treatment resistance and stages of resistance
Within the antidepressant users (as deﬁned above), treat-
ment resistance was assessed in GS:SFHS using only
individuals that had been prescribed at least one anti-
depressant at an adequate dose and duration (as above, n=
3452). Case status for treatment resistance was deﬁned as
those individuals who had been prescribed more than two
antidepressants providing 250 treatment resistant cases and
3202 non-treatment resistant controls. There have been
signiﬁcant difﬁculties deﬁning treatment resistant depres-
sion in research but the general consensus is that it should
be deﬁned as non-response to more than two anti-
depressants [30].
Individual response to antidepressants decreases with
more unsuccessful trials [3], it has therefore been suggested
that a semi-quantitative stages of resistance phenotype
might be more informative than a dichotomous approach
[31]. Stages of antidepressant resistance were deﬁned as the
number of different antidepressants prescribed given an
adequate dose and duration (as above). It was coded 1–4
with all individuals receiving more than four different
antidepressants assigned a value of 4. This deﬁnition
included 3452 individuals on antidepressants (2557, 645,
186 and 64 on 1, 2, 3 and 4+ antidepressants, respectively).
Whilst this deﬁnition takes into account the ﬁrst stage of the
Massachusetts General Hospital deﬁnition [29], it does not
account for augmentation or electroconvulsive therapy
(ECT) as these data were not available. This deﬁnition
therefore provides a semi-quantitative measure of resistance
based on the number of treatments taken, providing addi-
tional incremental information beyond our binary measure.
Genome-based therapeutic drugs for depression
GENDEP is a 12-week study that examined antidepressant
response in 867 individuals (mean age= 42.7, s.d.= 11.6)
taking escitalopram and noritriptyline. Response was mea-
sured by the Montgomery–Åsberg Depression Rating Scale
[32]. Antidepressant treatment resistance was deﬁned as
those who did not respond to more than 2 antidepressant
therapies including GENDEP treatments and previous
treatments (cases: 109, controls: 668), as described in a
previous study [33]. A full description of the cohort is
provided in Supplemental Table S3.
Genotyping, imputation and quality control
procedures
Generation Scotland: Scottish Family Health Study
Blood samples were stored and genotyped at the Wellcome
Trust Clinical Research Facility, Edinburgh (www.wtcrf.ed.
ac.uk). Details of the DNA extraction and genotyping have
been given elsewhere [34]. Imputation to a combined
reference panel of 1000 Genomes Phase 1 Version 3 and the
UK10K haplotype reference panels was completed using
Minimac3 and phasing was conducted utilising SHAPEIT2
[35]. All individuals were white British and multi-
dimensional scaling (MDS) components were also used to
identify and remove people who were relative outliers for
these measures of population ancestry. Quality Control
(QC) inclusion criteria were INFO > 0.9, missingness per
single nucleotide polymorphism (SNP) or individual < 1%,
Hardy-Weinberg equilibrium (HWE) P-value cut-off of >
1 × 10–6, minor allele frequency (MAF) > 1%. 7,395,460
SNPs and 3452 individuals (and 250 cases for treatment
resistance) passed QC criteria.
Genome-based therapeutic drugs for depression
DNA was extracted from blood samples and genotyped
using the Illumina Human610quad bead chip (Illumina,
Inc., San Diego). Imputation to the Haplotype
Reference Consortium (HRC) data version 1 reference
panel [36] was completed using Minimac3. QC
exclusion criteria were poor imputation quality (r2 < 0.3
(using the Markov Chain method [37])), missingness
per SNP > 5%, missingness per individual > 3%, MAF <
1%, related individuals (identity-by-descent > 0.188).
Individuals with gender discrepancies, abnormal hetero-
zygosity and population outliers were excluded.
7,518,836 SNPs and 761 individuals (108 cases) passed
QC criteria.
Statistical analysis
Bivariate analysis for all antidepressant users and MDD
Bivariate analysis was completed in GCTA v1.91.4 [38]
between all antidepressant users (as deﬁned above, n=
3452), and Structured Clinical Interview for DSM Disorders
(SCID)-diagnosed MDD (details in Supplementary Materi-
als) to assess the degree of shared genetic architecture
between these traits. Bivariate values were taken between
two variance component measures; genetics (G) and kinship
(K), which represent common genetics and pedigree-
associated genetics (including rare variants) respectively.
The G component is equivalent to methods used to measure
SNP heritability and K is an altered G with a pairwise
relatedness threshold less than 0.05 set to zero, this tech-
nique has been previously published [39]. The model was
controlled for age, sex and the ﬁrst four MDS components
ﬁtted to control for population stratiﬁcation. Statistical
signiﬁcance was estimated using the likelihood-ratio
test (LRT).
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Genome-wide association study
GWAS in GS:SFHS on antidepressant treatment resistance
and stages of resistance were completed utilising linear
mixed model analysis in GCTA (Genome-wide Complex
Trait Analysis) [38]. Age, sex and the ﬁrst four MDS
components were ﬁtted as covariates and, to account for the
family structure in GS:SFHS, genetic relationship matrices
(GRMs) were ﬁtted as random effects (see Supplemen-
tary Materials). To counter the loss of power that is caused
by inclusion of a candidate SNP as both a random effect (in
the GRM) and a ﬁxed effect, the leave-one-chromosome-
out method was utilised [40]. Due to the use of linear mixed
models on a binary trait, treatment resistance, Taylor series
transformation [41] was used to convert beta and standard
error values from the linear scale to the liability scale (see
Supplementary Materials).
GWAS in GENDEP was completed on unrelated indivi-
duals utilising logistic regression in PLINK [42]. Models were
corrected for age, centre, baseline severity and the ﬁrst four
principal components, to control for population stratiﬁcation.
Meta-analysis between GS:SFHS and GENDEP in anti-
depressant treatment resistance was completed in METAL
[43] with the inverse variance weighted method. A total of
7,120,598 SNPs were in common across both samples.
Gene and gene-set enrichment analysis
Gene and gene-set analysis were completed using MAGMA
(v1.04) [44] (further details in Supplementary Materials).
Individual level data were utilised for analysis of both
antidepressant treatment resistance and stages of resistance
in GS:SFHS and summary statistics data used for analysis
in GENDEP treatment resistance. Antidepressant treatment
resistance in GS:SFHS and GENDEP was then meta-
analysed in MAGMA using ﬁxed effect meta-analysis. To
map SNPs to gene and biologically-meaningful gene sets,
SNPs were annotated using NCBI 37.3 and, for the gene-set
analysis, gene-annotation ﬁles from the Gene Ontology
(GO) Consortium (http://geneontology.org/) were taken
from the Molecular Signatures Database (MSigDB) v5.2.
GO is an inclusive set of 5917 gene pathways that cover a
wide variety of functions, including molecular functions,
cellular components and biological processes. Gene sets
were corrected for multiple testing using the MAGMA
default setting correcting for 10,000 permutations.
Pedigree-based heritability
Pedigree-based heritability of antidepressant treatment
resistance and stages of resistance was calculated in R using
MCMCglmm [45]. This was achieved by constructing a
variance component matrix that takes into account all
pedigree information and then ﬁtting it into a univariate
model as a random effect. MCMCglmm uses a Bayesian
framework to estimate heritability. For treatment resistance,
the logit link function was used to account for the binary
nature of the phenotype.
Genetic correlation analysis
Genetic correlations were calculated using a bivariate ana-
lysis in ASReml-R (http://www.vsni.co.uk/software/asreml/).
Correlations between antidepressant treatment resistance and
stages of resistance were examined with eight personality
and cognitive variables; neuroticism, extraversion, schizoty-
pal personality questionnaire (SPQ), mood disorder ques-
tionnaire (MDQ), general cognitive ability (‘g’, formed from
four varied cognitive test scores), Scottish Index of Multiple
Deprivation (SIMD), education and the general health
questionnaire (GHQ). The ASReml-R method was utilised as
it can account for the family structure in GS:SFHS. Genetic
correlation measurements were calculated between pedigree-
based heritabilities as the sample sizes were too small to
conduct SNP-based correlations. More information on the
variables and methods used can be found in the
Supplementary Materials.
Polygenic risk scoring analysis
PRS were constructed utilising PLINK [42]. This method
has been previously described [46] and further information
is available in the Supplementary Materials. Summary sta-
tistics taken from the Psychiatric Genomics Consortium
(PGC) were used to construct PRS for MDD (unpublished
data, see Supplementary Materials), schizophrenia [47] and
bipolar disorder [48] in the GS:SFHS cohort to examine
genetic liability to the disorders in a treatment resistant
population. PRS were reported across ﬁve P-value thresh-
olds (<0.01, <0.05, <0.1, <0.5 and <1).
Association of PRS to the trait was analysed by linear
mixed model analysis in ASReml-R (http://www.vsni.co.
uk/software/asreml/) with antidepressant treatment resis-
tance or stages of resistance as the dependent variable and
PRS as the independent variable. All models were adjusted
for age, sex, and the ﬁrst four MDS components and, to
account for related individuals, an additive relationship
matrix (expected relatedness derived from pedigree infor-
mation) was ﬁtted as a random effect. Wald’s conditional F-
test was used to derive P-values for all ﬁxed effects (see
Supplementary Materials). Taylor series approximation [41]
was used for the treatment resistance variable, as above.
AVENGEME [49] was used to calculate power in the
PRS analysis assuming 5% of SNPs had an effect in the
training sample and all markers were independent. Two
theoretical covariances were tested at 0.5 and 0.25.
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Results
Genetic correlation of all antidepressant users and
MDD
Antidepressant use and MDD demonstrated signiﬁcantly
overlapping genetic architectures for both common (rg=
1.0, P= 0.026) and pedigree-related genetics (rk= 0.88,
P= 1.7 × 10−16, Supplemental Table S4). Both correlations
indicate that ‘any antidepressant use’ deﬁned from pre-
scription records using dose and duration ﬁlters is a
valid means of identifying a genetically representative
MDD population. Common genetics accounted for 0.10
(CI= 0.02 – 0.19) of the variance in antidepressant use (i.e.
Fig. 1 Manhattan and Q-Q plots of the GWAS of antidepressant
treatment resistance in (a) Generation Scotland: Scottish Family
Health Study, (b) Genome-based Therapeutic Drugs for Depression
and (c) the meta-analysis between the two cohorts. Genome-wide
signiﬁcance level (P < 5 × 10−8) is represented by a red line and sug-
gestive threshold (P < 1 × 10-5) is represented by a blue line
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SNP heritability) and pedigree-related genetics 0.43
(CI= 0.32 – 0.54), SCID MDD measurements in this cohort
have been previously reported (Zeng et al, [50], PMID=
27838479).
Genome-wide association study
In the antidepressant treatment resistance meta-analysis of
4213 individuals (cases= 358, controls= 3855), no SNP
reached genome-wide signiﬁcance (P > 5 × 10−8). The most
signiﬁcant SNP identiﬁed was an intergenic variant located
at 10p26.13 (lead SNP rs188352979, P= 3.25 × 10−7, OR
= 2.87, CI= 2.47–3.28; Fig. 1).
In the GWAS of stages of antidepressant resistance in
GS:SFHS (n= 3452), no SNP reached genome-wide sig-
niﬁcance (P > 5 × 10−8). The most signiﬁcant SNP identi-
ﬁed was an intergenic variant located at 10q22.1 (lead SNP
rs116902282, P= 1.5 × 10−7, beta= 0.49, s.e.= 0.076;
Fig. 2).
The top four loci for each GWAS below a P-value of 5 ×
10−7 for the antidepressant treatment resistance meta-
analysis and stages of antidepressant resistance can be
found in Table 1. Heterogeneity statistics for the treatment
resistance meta-analysis are also reported, we found either
no evidence or nominal evidence of heterogeneity between
GS:SFHS and GENDEP that was not signiﬁcant after
adjustment for multiple correction at a genome-wide level.
Gene and gene-set enrichment analysis
Gene-based analysis with MAGMA did not identify any
genes signiﬁcantly associated after false discovery rate
(FDR) multiple testing correction. Similarly, in the gene-set
analysis no gene-set passed multiple testing correction over
10,000 permutations. The most signiﬁcant genes and gene
sets are listed in Supplemental Table S5.
Pedigree-based heritability and genetic correlations
Pedigree-based heritability was calculated in GS:SFHS at
0.60 (CI= 0.22–0.87) for antidepressant treatment resis-
tance and 0.27 (CI= 0.24–0.31) for stages of antidepressant
resistance.
Signiﬁcant positive genetic correlations were found
between antidepressant treatment resistance and neuroticism
(rg= 0.66, PFDR= 0.0091), MDQ (rg= 0.86, PFDR=
0.0072) and GHQ (rg= 0.96, PFDR= 8.8 × 10–5). For stages
of antidepressant resistance, they were identiﬁed between
neuroticism (rg= 0.51, PFDR= 0.023), SPQ (rg= 0.44,
PFDR= 0.036), MDQ (rg= 0.69, PFDR= 0.027) and GHQ
(rg= 0.71, PFDR= 0.0011). All these correlations survived
correction for multiple testing with FDR (Table 2).
Genetic liability of psychiatric traits with
antidepressant treatment resistance and stages of
resistance using polygenic risk scores techniques
Antidepressant treatment resistance and stages of anti-
depressant resistance were positively and nominally asso-
ciated with MDD PRS at P-value thresholds (PT) 0.1, 0.5
and 1, and antidepressant treatment resistance only with
schizophrenia PRS at PT < 0.01. There were no signiﬁcant
associations between antidepressant treatment resistance or
stages of antidepressant resistance with bipolar disorder
PRS (Table 3). No result survived FDR correction and
power analyses indicated we were underpowered to detect
an association between MDD and bipolar disorder PRS with
antidepressant treatment resistance and stages of
Fig. 2 Manhattan and Q-Q plots of the GWAS of antidepressant stages of resistance. Genome-wide signiﬁcance level (P < 5 × 10−8) is represented
by a red line and suggestive threshold (P < 1 × 10−5) is represented by a blue line
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antidepressant resistance. Schizophrenia PRS was powered
to detect an association at all thresholds in both anti-
depressant treatment resistance and stages of resistance
given a genetic correlation of 0.5. At a genetic correlation
of 0.25, stages of antidepressant resistance had adequate
power at all thresholds whilst antidepressant treatment
resistance was only powered at PT 0.01 (Table 3).
Discussion
We utilised antidepressant prescription records to explore
common genetic factors in antidepressant treatment resis-
tance and stages of resistance in a population and family-
based cohort of 3452 individuals. In the treatment resis-
tance GWAS meta-analysis, the most signiﬁcant locus was
located at 10q26.13 at P= 3.3 × 10−7; lead SNP
rs188352979. This SNP is intergenic and lies in between
genes ACADSB and HMX3. ACADSB encodes short/bran-
ched chain speciﬁc acyl-CoA dehydrogenase (SBCAD)
which is an enzyme involved in the metabolism of fatty
acids [51]. Of interest, differences in mitochondrial fatty
acid metabolism have been found between ketamine
responders and non-responders in bipolar disorder [52].
HMX3 is a transcription factor that is involved in the spe-
ciﬁcation of neuronal cells needed for hypothalamus
development and hypothalamic–pituitary–adrenal (HPA)
axis [53]. Disruptions in the HPA axis are known to be
associated with MDD, MDD severity and antidepressant
response [55, 56]. A single locus at 10q22.1 was associated
with stages of antidepressant resistance at P= 1.71 × 10−7,
lead SNP rs116902282. This is an intergenic variant that
lies between functional genes C10orf35 and COL13A1.
C10orf35 is a protein coding gene that has previously been
associated with uterine leiomyoma [56]. COL13A1 encodes
the alpha chain of one of the nonﬁbrillar collagens. No
variant in either analysis reached the required threshold for
genome-wide statistical signiﬁcance (P > 5 × 10−8). Gene
and gene-set enrichment did not identify any signiﬁcant
associations with either antidepressant treatment resistance
or stages of resistance. Nonetheless, modest to high
pedigree-based heritability estimates indicate that 60% of
the variance in antidepressant treatment resistance and 27%
of the variance in stages of resistance can be explained by
genetics, although these estimates had large conﬁdence
intervals. This indicates that further exploration into genetic
contributions in antidepressant resistance is warranted.
Antidepressant treatment resistance was signiﬁcantly
and positively genetically correlated with neuroticism (rg
= 0.66), MDQ (rg= 0.86) and GHQ (rg= 0.96) indicating
overlapping genetic architecture between these traits. In
stages of antidepressant resistance, these same traits also
demonstrated signiﬁcant genetic correlation; neuroticismTa
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(rg= 0.51), MDQ (rg= 0.69) and GHQ (rg= 0.71), and we
additionally identiﬁed a signiﬁcant genetic correlation with
SPQ (rg= 0.44). We consider all correlations over 0.5 to be
high genetic correlation (as deﬁned previously [57]) and
therefore only identify one correlation not considered to be
so. The MDQ and SPQ correlation indicates that more
resistant individuals may share genetic components with
schizotypy and mood disorder personality traits. Genetic
overlap between psychological distress and antidepressant
resistance is indicative that individuals susceptible to dis-
tress are associated with a poorer outcome in anti-
depressants and should be further investigated.
Nevertheless, only a modest correlation was identiﬁed
between stages of antidepressant resistance and SPQ and it
is difﬁcult to ascertain causal inferences with any of these
correlations. Moreover, we did not ﬁnd any correlation in
antidepressant treatment resistance or stages of resistance
with general intelligence, education or social deprivation
traits, however, a lack of power due to small sample size (n
= 3452 with only 250 treatment resistant cases) may have
been major contributing factor.
Using PRS, we investigated whether poor response to
antidepressants indicate a higher liability to other mental
disorders (schizophrenia or bipolar disorder) as well as
higher genetic loading of MDD itself. We did not ﬁnd any
signiﬁcant association with antidepressant treatment resis-
tance or stages of resistance, however, power with the
current sample size was only adequate in analysis with
schizophrenia PRS at a genetic correlation of 0.5 and
additionally 0.25 for stages of antidepressant resistance.
Results for MDD and bipolar disorder PRS should therefore
be treated with caution, although the nominal associations
between MDD PRS and stages of antidepressant resistance
may be worth further investigation with larger sample sizes.
Interindividual variability in drug therapies can often be
attributed to genetic variability in cytochrome P450s
(CYP450) and metabolic transporters. In this study, we did
not identify any associations with metabolic variants and
response but it has been widely explored in previous lit-
erature, although inconsistent results have been reported for
both CYP450s [58] and metabolic transporters [59]. For
instance, nortriptyline has been widely demonstrated to
show differential serum level per CYP2D6 metaboliser type
(reviewed previously [58]), however a GENDEP study of
223 individuals taking escitalopram and 161 individuals
taking nortriptyline found that whilst serum levels of the
drugs varied per CYP450 genotype, treatment response was
not affected [60]. Nevertheless, it has been found that
CYP2D6 poor metabolisers have a higher proportion of side
effects [61]. Venlafaxine, however, has been more con-
sistently shown to have lower response and remission rates
amongst CYP2D6 poor metabolisers [62, 63]. This indicates
that, given access to larger samples, studies exploring
individual antidepressants may be beneﬁcial to identify
metabolic proﬁles that may or may not be affecting
response. Nonetheless, no GWAS to our knowledge has so
far implicated CYP450 in association with treatment
response.
One of the strengths of this study was that it used data
from a population-based cohort and is a good representation
of antidepressant users in a MDD sample in the general
Scottish population. Nevertheless, certain limitations of this
study should be noted. Although currently diagnosed schi-
zophrenia and bipolar patients were removed prior to this
analysis and minimum dose was matched to that of MDD
recommendations, it is possible that individuals were pre-
scribed the antidepressant for other conditions, e.g. anxiety
disorders, obsessive compulsive disorder (OCD), posttrau-
matic stress disorder (PTSD) and panic disorders, and may
have had a misdiagnosis in the ﬁrst instance. Nevertheless,
the high genetic correlation between all antidepressant users
and SCID-diagnosed MDD demonstrates that using pre-
scription records with dose and duration exclusions may be
a valid method of identifying large samples of proxy MDD
Table 2 Genetic correlations of
antidepressant treatment
resistance and stages of
resistance in Generation
Scotland: Scottish Family
Health Study with cognitive and
personality traits
Treatment resistance Stages of resistance
P-value PFDR rg (s.e.) N P-value PFDR rg (s.e.) N
Neuroticism 0.0034 0.0091 0.66(0.26) 3133 0.0058 0.023 0.51(0.19) 3133
Extraversion 0.78 0.78 −0.059 (0.22) 3133 0.71 0.71 −0.063 (0.17) 3133
SPQ 0.070 0.11 0.43(0.26) 1607 0.018 0.036 0.44(0.20) 1607
MDQ 0.0018 0.0072 0.86(0.36) 1715 0.010 0.027 0.69(0.28) 1715
GHQ 1.1× 10−5 8.8× 10−5 0.96(0.26) 3378 0.00014 0.0011 0.71(0.19) 3378
‘g’ 0.32 0.37 −0.16 (0.17) 3349 0.067 0.091 −0.24 (0.133) 3349
Education 0.13 0.17 −0.33 (0.23) 3233 0.40 0.46 −0.15 (0.18) 3233
SIMD 0.063 0.11 −0.22 (013) 3268 0.068 0.091 −0.18 (0.099) 3268
Signiﬁcant values after multiple testing correction (PFDR < 0.05) are shown in bold
FDR False discovery rate, rP phenotypic correlation, SPQ schizotypal personality questionnaire,MDQ mood
disorder questionnaire, GHQ general health questionnaire, SIMD Scottish index of multiple deprivation
E. M. Wigmore et al.
cases that are genetically representative of the disorder. It
was not possible to account for the use of psychotherapy or
ECT (which is advised in patients with severe MDD) and,
additionally, no exclusions were applied for the prescription
of other psychotropic medications used alongside anti-
depressants. It is therefore possible that other treatments
may have provided more information of response and non-
response to antidepressants. We were also only able to
obtain prescription records over a 6-year period meaning
there are likely to be some individuals who had prescrip-
tions before this period. Despite the 6-week threshold
applied here, individuals may also switch antidepressants
after 6 weeks continuous treatment, due to side effects such
as weight gain [64]. An additional limitation to this method
is that it does not account for combination therapies.
Although in the UK, combination therapies are often only
considered after failure of a second single trial of anti-
depressant monotherapy [27], therefore by the deﬁnition
adopted in this current study, they would also be considered
treatment resistant. Furthermore, because we integrate pre-
scribing data across a number of different antidepressant
drugs and classes, speciﬁc associations with treatment
resistance within or between classes of prescribed com-
pounds may have been missed. It should also be highlighted
Table 3 PRS associations with schizophrenia, bipolar disorder and MDD with antidepressant treatment resistance and stages of resistance
Treatment resistance Stages of resistance
Threshold P-value (PFDR) Stats Power at rg 0.5 (& 0.25) P-value (PFDR) Stats Power at rg 0.5 (& 0.25)
MDD
0.01 0.35 β= 0.25 0.17 0.45 β= 0.0055 0.44
(0.54) R2= 0.00030 (0.079) (0.57) R2= 0.00021 (0.15)
0.05 0.22 β= 0.0058 0.17 0.21 β= 0.0086 0.45
(0.46) R2= 0.00050 (0.080) (0.46) R2= 0.00051 (0.15)
0.1 0.042 β= 0.0017 0.17 0.049 β= 0.014 0.44
(0.21) R2= 0.0014 (0.079) (0.25) R2= 0.0013 (0.15)
0.5 0.012 β= 0.012 0.16 0.015 β= 0.017 0.41
(0.20) R2= 0.0020 (0.076) (0.15) R2= 0.0020 (0.14)
1 0.030 β= 0.060 0.16 0.020 β= 0.0160 0.40
(0.20) R2= 0.0015 (0.076) (0.15) R2= 0.0018 (0.14)
SCZ
0.01 0.027 β= 0.011 1.0 0.14 β= 0.010 1.0
(0.20) R2= 0.0017 (0.85) (0.36) R2= 0.00074 (1.0)
0.05 0.19 β= 0.0061 1.0 0.64 β= 0.0032 1.0
(0.46) R2= 0.00055 (0.75) (0.74) R2= 7.1 × 10−5 (1.0)
0.1 0.68 β= 0.0019 1.0 0.87 β= 0.0011 1.0
(0.68) R2= 5.3 × 10−5 (0.68) (0.87) R2= 8.1 × 10-6 (0.99)
0.5 0.40 β= 0.0038 0.98 0.48 β= 0.0047 1.0
(0.56) R2= 0.00021 (0.52) (0.60) R2= 0.00015 (0.95)
1 0.42 β= 0.0036 0.98 0.45 β= 0.0050 1.0
(0.56) R2= 0.00020 (0.50) (0.60) R2= 0.00018 (0.94)
BPD
0.01 0.57 β=−0.0025 0.25 0.70 β= 0.0026 0.64
(0.65) R2= 9.6 × 10−5 (0.099) (0.75) R2= 4.7 × 10−5 (0.21)
0.05 0.59 β= 0.0024 0.26 0.45 β= 0.0050 0.65
(0.65) R2= 8.6 × 10−5 (0.10) (0.60) R2= 0.00017 (0.22)
0.1 0.45 β= 0.0034 0.25 0.26 β= 0.0074 0.65
(0.56) R2= 0.00017 (0.099) (0.48) R2= 0.00038 (0.22)
0.5 0.23 β= 0.0053 0.24 0.11 β= 0.010 0.61
(0.46) R2= 0.00042 (0.095) (0.36) R2= 0.00074 (0.20)
1 0.23 β= 0.0053 0.23 0.13 β= 0.0097 0.60
(0.46) R2= 0.00041 (0.095) (0.36) R2= 0.00066 (0.20)
MDD Major depressive disorder, SCZ schizophrenia, BPD bipolar disorder, rg genetic correlation
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that, whilst antidepressant resistance measures were taken
over a 6-year period, mood and personality questionnaires
were taken at a single time point and may have been
impacted by mood or condition (e.g. currently having a
depressive episode) of the patient at the time of completing
the questionnaire. Lastly, differing covariates were applied
in the meta-analyses, e.g. baseline severity in the GENDEP
sample but not GS:SFHS.
Whilst the stages of antidepressant resistance measure
provide additional information above the binary treatment
resistance measure, it differs from models previously
deﬁned in the literature. Previous measures (such as the
Thase and Rush ﬁve-stage model [65], Massachusetts
General Hospital staging model [29] and the Maudsley
staging model [66]) are signiﬁcantly more detailed and
account for augmentation therapies, ECT, differing anti-
depressant classes and MDD severity. However, there has
also been criticism of these measures as they have arbitrary
thresholds and have not been widely validated [67]. In this
study, our staging measure was deﬁned solely on anti-
depressant switching, due to limitations in the available
data. This measure is therefore not synonymous with other
deﬁnitions used in prior studies. Nevertheless, there is no
uniformly accepted method of quantifying the degree of
antidepressant resistance and this measure will likely cap-
ture useful information regarding resistance to anti-
depressant treatment.
Despite an increased sample size compared to those
reported in previous clinical studies of antidepressant
response (n= 2897), our numbers are still small for a
GWAS and it is likely that we were underpowered. With an
increasing availability of electronic records in large bio-
banks and numerous smaller antidepressant studies, a col-
laborative effort approach may be required in order to
increase sample size for adequate power. To replicate our
analysis with adequate power (>0.8) at a MAF of 0.01, it
would require a sample size of 7596 cases for anti-
depressant treatment resistance and 9660 total sample for
stages of resistance assuming an OR of 1.6 and beta of 0.3,
respectively (Supplemental Table S6; power calculations
were completed using QUANTO v1.2). Furthermore, the
epigenetic of treatment resistance could be further explored.
Recent studies have indicated that methylation levels have
been predictive of overall response [68].
With increasing accessibility of electronic health
records [69], access to prescription records is becoming
possible. In this study, we explored the possibility of uti-
lising this prescription data to examine resistance to anti-
depressant treatment by inferring drug switching as non-
response. We have provided evidence that resistant indivi-
duals have a high genetic correlation with
neuroticism, psychological distress, schizotypy and mood
disorder traits. Furthermore, we demonstrate the need for
larger cohorts and collaboration in order to maximise
sample size. This study demonstrates the value of this
method and, as larger cohort sizes become available, the
results of such studies could further inform clinical and
research applications.
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